ZA200002514B - Process for cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine. - Google Patents

Process for cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine.

Info

Publication number
ZA200002514B
ZA200002514B ZA200002514A ZA200002514A ZA200002514B ZA 200002514 B ZA200002514 B ZA 200002514B ZA 200002514 A ZA200002514 A ZA 200002514A ZA 200002514 A ZA200002514 A ZA 200002514A ZA 200002514 B ZA200002514 B ZA 200002514B
Authority
ZA
South Africa
Prior art keywords
tetrahydronaphthalen
pyrrolidine
phenoxy
cis
methoxy
Prior art date
Application number
ZA200002514A
Other languages
English (en)
Inventor
Charles Kwok-Fung Chiu
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200002514B publication Critical patent/ZA200002514B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/48—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation involving decarboxylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200002514A 1999-05-24 2000-05-22 Process for cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine. ZA200002514B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13557899P 1999-05-24 1999-05-24

Publications (1)

Publication Number Publication Date
ZA200002514B true ZA200002514B (en) 2002-02-22

Family

ID=22468706

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200002514A ZA200002514B (en) 1999-05-24 2000-05-22 Process for cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine.

Country Status (24)

Country Link
US (3) US6232476B1 (enExample)
EP (1) EP1055658B1 (enExample)
JP (2) JP3296809B2 (enExample)
KR (1) KR100388176B1 (enExample)
CN (3) CN1226265C (enExample)
AR (1) AR035990A1 (enExample)
AT (1) ATE234269T1 (enExample)
AU (1) AU769690B2 (enExample)
BR (1) BR0001813B1 (enExample)
CA (1) CA2308922C (enExample)
DE (1) DE60001599T2 (enExample)
DK (1) DK1055658T3 (enExample)
ES (1) ES2191597T3 (enExample)
HU (1) HUP0001988A3 (enExample)
ID (1) ID26146A (enExample)
IL (1) IL136231A (enExample)
IN (1) IN188849B (enExample)
PL (1) PL340237A1 (enExample)
PT (1) PT1055658E (enExample)
RU (1) RU2195445C2 (enExample)
TR (1) TR200001476A2 (enExample)
TW (1) TWI231295B (enExample)
YU (1) YU26700A (enExample)
ZA (1) ZA200002514B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
CA2479924C (en) * 2002-03-28 2008-07-15 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
JP5212931B2 (ja) * 2006-01-26 2013-06-19 学校法人東京理科大学 ラソフォキシフェン及びその類縁体の製造方法
CZ2007373A3 (cs) * 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
CN102424661A (zh) * 2011-10-21 2012-04-25 南开大学 一种偶氮类色素半抗原与人工抗原的合成方法
CN103113323B (zh) * 2013-02-05 2015-11-11 南京华威医药科技开发有限公司 酒石酸拉索昔芬中间体的制备方法
CN110099680B (zh) 2016-10-11 2021-02-05 杜克大学 Er+乳腺癌的拉索昔芬治疗
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2025043004A1 (en) 2023-08-21 2025-02-27 Duke University Treatment of solid cancer with lasofoxifene
WO2026095931A1 (en) 2024-10-30 2026-05-07 Sermonix Pharmaceuticals, Inc. Neoadjuvant treatment of er+ breast cancer with lasofoxifene
WO2026096820A1 (en) 2024-10-30 2026-05-07 Sermonix Pharmaceuticals, Inc. Neoadjuvant treatment of er+ breast cancer with lasofoxifene

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
US3522319A (en) 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
FR2678938B1 (fr) * 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa Derives de pyrrolidine, leur preparation et les medicaments les contenant.
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5552241A (en) * 1995-05-10 1996-09-03 Electrochemical Systems, Inc. Low temperature molten salt compositions containing fluoropyrazolium salts
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
ATE240942T1 (de) * 1995-11-17 2003-06-15 Merck & Co Inc Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
CA2298651A1 (en) * 1997-08-07 1999-02-18 Jeffrey Alan Dodge 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin

Also Published As

Publication number Publication date
EP1055658A2 (en) 2000-11-29
JP2000327670A (ja) 2000-11-28
JP2002205990A (ja) 2002-07-23
CA2308922C (en) 2007-05-01
US20020042524A1 (en) 2002-04-11
EP1055658B1 (en) 2003-03-12
CN1271030C (zh) 2006-08-23
AU3636200A (en) 2000-11-30
US6232476B1 (en) 2001-05-15
JP3600206B2 (ja) 2004-12-15
TR200001476A2 (tr) 2001-02-21
EP1055658A3 (en) 2000-12-13
KR100388176B1 (ko) 2003-06-19
ID26146A (id) 2000-11-30
ES2191597T3 (es) 2003-09-16
KR20010029733A (ko) 2001-04-16
TWI231295B (en) 2005-04-21
PL340237A1 (en) 2000-12-04
CN1502598A (zh) 2004-06-09
HU0001988D0 (en) 2000-08-28
YU26700A (sh) 2002-06-19
US6323345B1 (en) 2001-11-27
AR035990A1 (es) 2004-08-04
CN1226265C (zh) 2005-11-09
US6395911B1 (en) 2002-05-28
DK1055658T3 (da) 2003-04-22
IL136231A (en) 2005-06-19
RU2195445C2 (ru) 2002-12-27
DE60001599D1 (de) 2003-04-17
IN188849B (enExample) 2002-11-09
CN1280128A (zh) 2001-01-17
BR0001813A (pt) 2001-01-02
HUP0001988A2 (en) 2001-03-28
HUP0001988A3 (en) 2002-04-29
DE60001599T2 (de) 2003-11-13
IL136231A0 (en) 2001-05-20
BR0001813B1 (pt) 2011-03-22
CA2308922A1 (en) 2000-11-24
AU769690B2 (en) 2004-01-29
JP3296809B2 (ja) 2002-07-02
HK1061843A1 (en) 2004-10-08
CN1502597A (zh) 2004-06-09
PT1055658E (pt) 2003-07-31
ATE234269T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
ID28489A (id) Metode untuk membuat 4-karboksiamino-2-disubstitusi 1,2,3,4-tetrahidroquinolin
IL136231A0 (en) Process for cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy] ethyl} pyrrolidine
AU6200199A (en) Process for preparing 1,3-propanediol from methyl 3-hydroxypropionate
ZA972973B (en) Substituted [2-(1-piperazinyl)ethoxy]methyl compounds.
ZA200007253B (en) Process for preparing 1,4-dihydropyridine compounds.
HUP9902530A3 (en) New process for producing 4-(1-hydroxyl-1-methyl-ethyl)-furane-2-sulfonamide, and intermediates
IL115895A0 (en) Process for preparing 5-chloro-2,3-dihydro-1h-inden-1-one
HUP0200144A3 (en) Process for preparing pesticidal 5-amino-1-aryl-3 cyanopyrazole derivatives, and the new intermediates
IL137214A (en) E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl) phenoxy] ethanol and pharmaceutical compositions thereof
EG24052A (en) Novel processes for the preparation of (r)-a (2,3-demethoxyphenyl-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethapnol
ZA992631B (en) Process for preparing hydroxamic acids.
PL348036A1 (en) Tissue paper product, and process for making the product
IL160749A0 (en) Process and intermediate for cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl-) phenoxy] ethyl}pyrrolidine
HUP0103002A3 (en) New process for obtaining 17betha-(n-terc-butylcarbamoyl)-3-one-4-aza-steroids
ZA200103191B (en) Vancoresmycin, a process for its production and its use as a pharmaceutical.
IL146810A0 (en) Process for preparing 10, 11-methanobenzosuberane derivatives
AU6086998A (en) Process for preparing 1,4-disubstituted piperidine compounds
GB9914600D0 (en) Novel,process
EG22719A (en) Catalytic vacuum distillation process
ZA200110137B (en) Phenoxypropylamine compounds.
EG22464A (en) Process for making 1,3-disubstituted-4-oxocyclic ureas
AU9073098A (en) Process for obtaining 2-(4-(4-(m- ethylsulfonamido-phenyl) piperazine-1-yl) butyl)-1,3- dioxoperhydroyrrolo (1,2-c)imidazol
ITTN990010A1 (it) Igenik, coperchio per lattine
MXPA01012227A (es) Gabinete manifrac para 23 kv, 400 amperes.
ZA200005017B (en) 1-[1-substituted-4-piperidnyl)methyl]-4-piperidine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermidiate therefor.